Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1996-09-24
1999-09-21
MacMillan, Keith D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
514171, 514360, 514547, 514925, 424 7805, A61K 4382
Patent
active
059554517
ABSTRACT:
Disclosed are compositions comprising non-steroid anti-inflammatory drugs (NSAID'S) complexed with zwitterionic, neutral phospholipids, or both, having reduced gastrointestinal irritating effects and enhanced antipyretic, analgesic, and antiinflammatory activity. Also disclosed are improved methods of using the complexes for treating fever, inflammation, and preventing platelet aggregation. In some embodiments, the anti-pyretic activity of sub-therapeutically used amounts of NSAID's are enhanced to elicit anti-pyretic activity in vivo when associated (noncovalently) with zwitterionic phospholipids, such as dipalmitoyl phosphatidyl choline. Methods and compositions useful for enhancing the therapeutic activity of non-steroidal anti-inflammatory agents in the presence of anti-secretory agents are also discussed.
REFERENCES:
patent: 4279906 (1981-07-01), Frosch
patent: 4309420 (1982-01-01), Ghyczy et al.
patent: 4332795 (1982-06-01), Ghyczy et al.
patent: 4369182 (1983-01-01), Ghyczy et al.
patent: 4378354 (1983-03-01), Ghyczy et al.
patent: 4421747 (1983-12-01), Ghyczy et al.
patent: 4528193 (1985-07-01), Ghyczy et al.
patent: 4684632 (1987-08-01), Schulz et al.
patent: 4687766 (1987-08-01), Wendel et al.
patent: 4918063 (1990-04-01), Lichtenberger et al.
patent: 5032585 (1991-07-01), Lichtenberger
Author unknown, "Press Digest for Nature Medicine," Nature Medicine, pp. 1-4, in particular, p. 2, Feb., 1995.
Clarke, et al., "Antinociceptive effects of non-steroidal anti-inflammatory drugs in a rat model of unilateral hindpaw inflammation," European Journal of Pharmacology 257 (1994) 103-108.
Davis, et al., "Processed Aloe vera administered Topically Inhibits Inflammation," Journal of the American Podiatric Medical Assocation, vol. 79, No. 8 (Aug., 1989) 395-397.
Dial, et al., "Gastroprotective Activity of Dietary Lipids," AGA Abstracts, pp. A61, Apr., 1992.
Dialog Search Report, pp. 1-24, dated Jan. 9, 1995, 3:50 p.m.
Dialog Search Report, pp. 1-6, dated Jan. 9, 1995, 3:19 p.m.
Dialog Search Report, pp. 1-66, dated Jan. 9, 1995, 2:03 p.m.
Giraud, et al., "Zwitterionic phospholipids facilitate the transport of aspirin across artificial membranes," Gastroenterology, vol. 108, No. 4, A101, 1995.
Glenn, et al., "Simple Laboratory Procedures for the Evaluation of Topically-Active Anti-Inflammatory Drugs," Agents and Actions, vol. 8/5 (1978) 497-503.
Go, et al., "Gastric Mucosal Hydrophobicity and Helicobacter Pylori: Absence of a Direct Relation?" AGA Abstracts: 102(4) (Part 2), Apr., 1992.
Lichtenberger, et al., "ASA Forms An Ionic Complex With Phosphatidylcholine: Possible Molecular Explanation For Its Ulcergenic Action," Gastroenterology, vol. 104, No. 4, Part 2, A134, AGA Abstracts, 1993.
Lichtenberger, et al., "Certain NSAIDS Chemically Associate With Surface Phospholipids: Insight Into Mechanism And Reversal of NSAID-Induced Gastric Injury," Gastroenterology, vol. 106, A125, 1994.
Lichtenberger, et al., "NSAIDs complexed to phosphatidylcholine have reduced GI toxicity and enhanced bioavailability," Gastroenterology, vol. 108, No. 4, A149, 1995.
Lichtenberger, et al., "Effect of naproxen on gastric mucosal hydrophobicity: possible interaction with surface phospholipids," Gastroenterology: vol. 108, No. 4, A149, 1995.
Lichtenberger, et al., "Ammonium (NH.sub.4+) Prevents the Denovo Formation of a Phospholipid (PL) Monolayer Surface: Is This the Basis of H. Pylori-Induced Reduction in Gastric Mucosal Hydrophobicity?" AGA Abstracts, pp. A653, Apr., 1992.
Lichtenberger, et al., "Chronic Elevation of Intraluminal Ammonia Induces Gastroduodenal (G-D) Hypertrophy and a Defect in the Mucosal Barrier," AGA Abstracts, Apr., 1992.
Lichtenberger, et al., "Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Associate with Zwitterionic Phospholipids: Insight Into the Mechanism and Reversal of NSAID-Induced Gastrointestinal Injury," Nature Medicine, 1(2): 154-158, 1995.
Lichtenberger, et al, "Zwitterionic Phospholipids Enhance Aspirin's Therapeutic Activity, as Demonstrated in Rodent Model Systems," JPET, 277:1221-1227, 1996.
Rhone-Poulenc Rorer, Nattermann Phospholipid GMBH, "1. Lecithin: Definitions and Descriptions," Phospholipids and Liposomes, published after 1990.
Wang, "Zwitterionic Surfactant," Light Industrial Press, China (1991) A copy is not available; see I.D.S. for discussion).
International Search Report.
Liversidge, et al., "Influence of Indomethacin Amphoteric Gel on Gastric Ulcerogenicity and Absorption of Indomethacin In Rats," Pharm. Res., 6(1): 44-48, 1989, Database Chemical Abstracts on STN, AN 1989:107568.
Chemical Abstracts AN 1989: 107568, Liversidge et al, 1989.
Chemical Abstracts AN 1983:172935, Lind et al, 1983.
International Search Report, mailed May 1996.
Butler Bruce D
Lichtenberger Lenard
MacMillan Keith D.
Mayfield Denise L.
The University of Texas System & Board of Regents
LandOfFree
Methods of enhancing the therapeutic activity of NSAIDS and comp does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of enhancing the therapeutic activity of NSAIDS and comp, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of enhancing the therapeutic activity of NSAIDS and comp will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-80382